Virginia Oncology Associates

Hampton, Virginia 29303

4 studies enrolling now · 25 studies all time

What they study most

Breast Cancer, CD33 Positive Acute Myelogenous Leukemia, Castration-Resistant Prostate Cancer, Colorectal Cancer, Early Breast Cancer, Esophageal Adenocarcinoma, Gastroesophageal Junction Cancer, KEAP1 Gene Mutation, Kidney Neoplasms, Melanoma, Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer (mCRPC)

Studies at this site

• Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer — Recruiting now
• Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer — Recruiting now
• Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Recruiting now
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors — Completed
• A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression — Completed
• ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer — Completed
• Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer — Completed
• A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer — Completed
• A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer — Completed
• NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial — Stopped early
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) — Completed
• A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer — Completed
• Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer — Stopped early
• Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer — Completed
• A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer — Completed
• Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy — NO_LONGER_AVAILABLE
• Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. — Completed
• Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer — Completed
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer — Completed
• Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy — Completed
• A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer — Completed
• Efficacy Study of ABR-215050 to Treat Prostate Cancer — Completed
• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors — Completed
• Triple Negative Breast Cancer Biomarker Study — Completed